GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: BIIB
Neutral
up 36.00 %

Biogen Idec Inc (NASDAQ: BIIB) downgraded to Neutral by Piper Jaffray

Wednesday,  Jul 22, 2015  10:25 AM ET by Kristen Bailey

Here is more proof that the Piper Jaffray rating can guide you in smart investing. Piper Jaffray downgraded Biogen Idec Inc (NASDAQ: BIIB) to Neutral
with today's price of $397.11. Piper Jaffray rated Biogen Idec Inc (NASDAQ: BIIB) to Overweight on 11/27/2013, when the price was $292.69. Biogen Idec Inc's stock price gained 36% since then.
By following the previous Piper Jaffray's recommendation on BIIB, you would have gained 36% in 602 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy